anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND GOALS: One of the biggest difficulties facing healthcare systems today is the prevalence of multiple chronic diseases (MCC). Mortality and the development of new chronic illnesses are more likely in those with MCC. Pre-existing diseases and risk factors specific to the patient have an impact on the complex stochastic process that guides the evolution of MCC. This study's goal is to use a brand-new Graph Neural Network (GNN) model to examine the connections between specific chronic illnesses, patient-level risk factors, and pre-existing conditions.
METHODS: We propose a graph neural network model to analyze the relationship between five chronic conditions (diabetes, obesity, cognitive impairment, hyperlipidemia, and hypertension). The proposed model adds a graph Laplacian regularization term to the loss function, which aims to improve the parameter learning process and accuracy of the GNN based on the graph structure. For validation, we used historical data from the Cameron County Hispanic Cohort (CCHC).
RESULTS: Evaluating the Laplacian regularized GNN on data from 600 patients, we expanded our analysis from two chronic conditions to five chronic conditions. The proposed model consistently surpassed a baseline GNN model, achieving an average accuracy of ≥89% across all combinations. In contrast, the performance of the standard model declined more markedly with the addition of more chronic conditions. The Laplacian regularization provided consistent predictions for adjacent nodes, beneficial in cases with shared attributes among nodes.
CONCLUSIONS: The incorporation of Laplacian regularization in our GNN model is essential, resulting in enhanced node categorization and better predictive performance by harnessing the graph structure. This study underscores the significance of considering graph structure when designing neural networks for graph data. Future research might further explore and refine this regularization method for various tasks using graph-structured data.
Risk Summary

The limited data on the use of SPEVIGO in pregnant women are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. Human IgG is known to cross the placental barrier; therefore, SPEVIGO may be transmitted from the mother to the developing fetus. In an animal reproduction study, intravenous administration of a surrogate antibody against IL36R in mice during the period of organogenesis did not elicit any reproductive toxicity (see Data).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

Embryo-fetal development and pre- and postnatal development toxicity studies were performed in mice using a surrogate mouse specific IL36R antagonist monoclonal antibody. In the embryo-fetal development study, the surrogate was administered intravenously at doses up to 50 mg/kg to pregnant female mice twice weekly during the period of organogenesis. The surrogate was not associated with embryo-fetal lethality or fetal malformations. In the pre- and postnatal development toxicity study, the surrogate was administered intravenously at doses up to 50 mg/kg to pregnant female mice twice weekly from gestation day 6 through lactation day 18. There were no maternal effects observed. There were no treatment-related effects observed on postnatal developmental, neurobehavioral, or reproductive performance of offspring.
Participant is asked to chew on a study device (Oral Capsule) with their molar teeth which will draw saliva into the device's internal specimen chamber. This specimen will undergo respiratory pathogen panel PCR testing and COVID-19 antibody testing.
Run-in period (56 days): participants will receive vemurafenib 960 mg orally BID from Day 1 to 49 and vemurafenib 720 mg orally BID from Day 50 to 56. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg intravenous (IV) q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
Participants were randomized to receive oral cinacalcet once daily and placebo intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 30 mg daily and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
* Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (seeWARNINGSandPRECAUTIONS). 
  * The use of benzodiazepines, including diazepam rectal gel, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing diazepam rectal gel and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (seeWARNINGS). 
  * The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although diazepam rectal gel is indicated only for intermittent use (seeINDICATIONS AND USAGEandDOSAGE AND ADMINISTRATION), if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of diazepam rectal gel may precipitate acute withdrawal reactions, which can be life-threatening. For patients using diazepam rectal gel more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue diazepam rectal gel (see WARNINGS).
Delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH) is a major cause of complications and death. Here, we set out to identify high-performance predictive biomarkers of DCI and its underlying metabolic disruptions using metabolomics and lipidomics approaches. This single-center prospective observational study enrolled 61 consecutive patients with severe aSAH; among them, 22 experienced a DCI. Nine patients without aSAH were included as validation controls. Blood and cerebrospinal fluid (CSF) were sampled within the first 24 h after admission. We identified a panel of 20 metabolites that, together, showed high predictive performance for DCI. This panel of metabolites included lactate, cotinine, salicylate, 6 phosphatidylcholines, and 4 sphingomyelins. The interplay of the metabolome and the lipidome found between CSF and plasma in our patients underscores that aSAH and its associated DCI complications can extend beyond cerebral implications, with a peripheral dimension as well. As an illustration, early biological disruptions that might explain the subsequent DCI found systemic hypoxia driven mainly by higher blood lactate, arginine, and proline metabolism likely associated with vascular NO and disrupted ceramide/sphingolipid metabolism. We conclude that targeting early peripheral hypoxia preceding DCI could provide an interesting strategy for the prevention of vascular dysfunction.
Circular RNAs (circRNAs) are endogenous non-coding RNAs with a covalently closed loop structure. They have many biological functions, mainly regulatory ones. They have been proven to modulate protein-coding genes in the human genome. CircRNAs are linked to various diseases like Alzheimer's disease, diabetes, atherosclerosis, Parkinson's disease and cancer. Identifying the associations between circular RNAs and diseases is essential for disease diagnosis, prevention, and treatment. The proposed model, based on the variational autoencoder and genetic algorithm circular RNA disease association (VAGA-CDA), predicts novel circRNA-disease associations. First, the experimentally verified circRNA-disease associations are augmented with the synthetic minority oversampling technique (SMOTE) and regenerated using a variational autoencoder, and feature selection is applied to these vectors by a genetic algorithm (GA). The variational autoencoder effectively extracts features from the augmented samples. The optimized feature selection of the genetic algorithm effectively carried out dimensionality reduction. The sophisticated feature vectors extracted are then given to a Random Forest classifier to predict new circRNA-disease associations. The proposed model yields an AUC value of 0.9644 and 0.9628 under 5-fold and 10-fold cross-validations, respectively. The results of the case studies indicate the robustness of the proposed model.
The patients swallowed the first-generation MCCG with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination twice, the endoscopist controlled the capsule to face the pylorus and drag it close to the pylorus. The capsule would enter the duodenal bulb and was held stationary to investigate the duodenal bulb using the "360-degree automatic scanning" mode. In the descending part of duodenum, the endoscopist tried to control the capsule to view the major papilla. After passing through the duodenum, the capsule started to complete the small-bowel examination with the "small-bowel mode". The magnetic steering time for passing through the pylorus was not allowed more than 15 min.
The invention discloses a drug composition for treating red skin disease of grass carp. The drug composition comprises the following traditional Chinese medicine in parts by weight: 10 to 30 parts of humulus japonicus, 20 to 30 parts of euphorbia humifusa, 2 to 10 parts of melia azedarach leaves, 20 to 25 parts of herba houttuyniae, 2 to 10 parts of hinoki leaves and 2 to 7 parts of garlic. The invention further discloses a preparation method of the drug composition. According to the drug composition for treating red skin disease of the grass carp, the effective constituents of lupulone and humulone in the humulus japonicus have obvious inhibiting effects on gram positive bacteria such as staphylococcus aureus, streptococcus faecalis, streptococcus pneumoniae, corynebacterium diphtheriae, bacillus anthracis, bacillus subtilis and bacillus cereus in vitro. In the preparation method, a supercritical CO2 extraction method is adopted to extract effective constituents from humulus japonicus, so that activity of the effective constituents of the humulus japonicus is reserved, and the content is higher. The preparation method provided by the invention is simple and practical, and is suitable for large-scale production.
Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
BACKGROUND: Chronic wasting disease (CWD) is a fatal transmissible spongiform encephalopathy in cervids. The disease is caused by a pathogenic prion, namely PrPSc. Currently, diagnosis of CWD relies on IHC detection of PrPSc in the obex or retropharyngeal lymph nodes (RPLN) or ELISA screening of obex and RPLN followed by IHC confirmation of positive results. In this study, we assessed the performance characteristics of two immunoassays: CWD Ag-ELISA and TeSeE ELISA, RT-QuIC, and MEMS biosensor via testing 30 CWD + and 30 CWD- white-tailed deer RPLN samples.
RESULTS: Both CWD Ag-ELISA and TeSeE ELISA correctly identified all CWD + and CWD- samples. A greater intra-assay coefficient of variation (CV) in S/P ratios was observed for the TeSeE ELISA (16.52%), compared to CWD Ag-ELISA (9.49%). However, the high CV did not affect the qualitative results of triplicate assays when the corresponding manufacturer's cutoff was used. The MEMS biosensor not only correctly identified all CWD + and CWD- RPLN samples, but also demonstrated a 100% detection rate for all CWD + samples at dilutions from 10- 0 to 10- 3. Evaluation of RT-QuIC indicated that the rate of false negative reactions decreased from 21.98% at 10- 2 dilution to 0% at 10- 4 and 10- 5 dilutions; and the rate of false positive reactions reduced from 56.42% at 10- 2 dilution to 8.89% and 2.22% at 10- 4 and 10- 5 dilutions, respectively. Based on a stringent threshold of 2 x the first 10 fluorescent readings of each well and a final cutoff of 2/3 positive reactions for each sample, RT-QuIC correctly identified all positive and negative samples at 10- 4 and 10- 5 dilutions. Both MEMS biosensor and RT-QuIC achieved 100% sensitivity and 100% specificity under the experimental conditions described in this study.
CONCLUSIONS: The two immunoassays (CWD Ag-ELISA and TeSeE ELISA) performed comparably on white-tailed deer RPLN samples. MEMS biosensor is a reliable portable tool for CWD diagnosis and RT-QuIC can be used for routine testing of CWD if appropriate testing parameters and interpretive criteria are applied.
Blood transfusion is commonly performed in patients submitted to cardiac surgery. However, there are many studies reporting adverse effects of this intervention and final data on benefits are not available. There are no prospective studies in cardiac surgery regarding red blood cell transfusions requirements. There are retrospective studies in cardiac surgery suggesting worse outcomes including higher rates of mortality in patients submitted to red blood transfusion. Hematocrit levels around 30% are usually recommended not evidence based. Our purpose is to prospectively evaluate two strategies of transfusion in 500 patients submitted to elective cardiac surgery: a liberal strategy - patients receive blood transfusion when hematocrit is lower than 30% since the intraoperative period until the ICU discharge; a restrictive strategy - patients receive blood transfusion only when hematocrit is lower than 24%.

Clinical outcomes, costs and quality of life will be compared.
Participants who meet the eligibility criteria at screening will enter a 4-to 6-week Qualifying Period. The allowed concomitant antianginal medication(s) must be maintained at a stable dose throughout the study. Participants will document the number of angina episodes, number of sublingual nitroglycerin doses taken, and a dyspnea score (on a scale from 1 to 5) on a daily basis in a diary. Participants eligible to stay in the study after the Qualifying Period will enter the 8-week double-blind dosing phase. Participants will have study visits at the end of Weeks 2 and 8. Participants will continue to document the number of angina episodes and number of sublingual nitroglycerin doses taken as well as a dyspnea score on a daily basis by the end of each day in their diary. In addition, participants will be called during Week 2 and at the end of Week 5 to encourage compliance. A safety follow-up phone call will be made 14 days after the last study visit or early discontinuation.
Sensory hypersensitivity (SHS) is a frequently heard complaint after acquired brain injury (ABI) and is related to reduced quality of life and physical and mental health. This study aimed to identify triggers for SHS after ABI and investigate how individuals cope with SHS. Nineteen adults with ABI took part in 45-min individual interviews. Data were audio-recorded and transcribed verbatim. Inductive thematic analysis revealed five themes: (1) A mismatch between resources and demands, (2) Altered experience of ordinary stimuli, (3) It affects all aspects of living, (4) Avoid, approach, accept, (5) It's highly heterogeneous. A model explaining the impact of triggers on subjective SHS after ABI is proposed, which states that SHS arises from a mismatch between the demands of a sensory environment (triggers) and the available biopsychosocial resources of an individual to meet these demands. The elicited SHS can affect and be affected by levels of fatigue, which limits the resources and creates a loop. Coping strategies can act on various stages of this model, i.e., to reduce the mismatch and potentially alter the loop. This model can contribute to the identification of mechanisms behind SHS in ABI patients and other populations, ultimately leading to evidence-based treatments.
Two study visits will be completed with wheezing subjects. The baseline visit will be completed within a 5 day window from the child's discharge from the emergency department. The follow-up visit will be completed 3 months after the baseline visit. At both visits, participants will provide a nasal swab and urine sample, complete three breathing tests: multiple-breath washout, forced oscillation technique, and Spirometry. In addition, at the follow-up visit, children will have an allergy skin test done, a nasal brush to collect epithelial cells and provide a blood sample. Whole blood will be used for basophil activation test (BAT). Children age 4+ will also complete post-bronchodilator testing using Salbutamol to capture information about bronchodilator response.
A wellness platform for user fitness with a customizable, self-contained gym space having one or more physical training equipment assemblies. The physical training equipment assemblies may be conventional gym equipment and may also be equipment with health monitors which may further be operationally coupled to user computerized devices. The self-contained gym space and the physical training equipment are designed to employ one or more on-platform activity sensors, operationally coupled to at least one computer system. One or more activity recommendation systems are designed to recommend physical training equipment assemblies, nutrition, and psychological exercises and are designed to present wellness platform data, the data that may be used with machine learning systems, the machine learning systems designed to assess past and present performance and recommend future activities and targets. Off-platform sensors may be monitored. Environmental controls may be activated. Added are aquatic training systems which include pools.
PURPOSE:To obtain the titled neutralizing substance F1 as a raw material having high safety inexpensively, by fermenting milk with a mold of Bifidobacterium or lactic acid bacteria, removing protein to be coagulated with an acid from a centrifugal supernatant liquid of the prepared fermented milk, subjecting the residue to salting-out with ammonium sulfate, etc. CONSTITUTION:Milk is fermented with a mold of Bifidobacterium or lactic acid bacteria having ability to produce a substance for neutralizing toxin. The mold and protein to be coagulated with an acid are removed from the fermented milk by centrifugation, etc. The residue is subjected to salting-out with 50% saturated ammonium sulfate, a precipitated fraction is collected, the fraction is subjected to fractionation of molecular weight by gel fitration method, a fraction having >=1.5X10<6>mol.wt. is collected, to give a substance for neutralizing toxin of cholera and toxin of Escherichia coli. F1 is a mixture consisting essentially of glycoprotein and glycolipid, has >=1.5X10<6>mol.wt., content of glycoprotein: shown by the table I , content of protein: shown by the table II, content of glycolipid: 64.8wt%, and stability: shown by the table III.
Developing effective treatment modalities is crucial in managing HCC patients with unresectable intermediate stage. Nowadays, many therapies have been used for treating this group of HCC patients, including TACE. However, residual tumors after TACE are not uncommon. In conventional, re-TACE is recommended for managing residual tumors. However, accumulated overall survival is still poor in consecutive TACEs, leading to a low rate of \<20% in 5 years.

In this regard, radiotherapy has been proved to be effective in managing HCC patients, especially a novel technique named SABR. When compared with conventional-fractionated radiotherapy, SABR demonstrated better treatment responses with fewer side effects in managing primary or metastatic liver tumors. In the literature, phase I and II trials of TACE plus SABR showed excellent local control rates and promising 1- and 2-year survival rates. However, till now, there is no head-to-head comparison between TACE + SABR and consecutive TACEs.
Symptoms of traumatic duodenal intramural hematoma, a rare disease caused by trauma, blood disease, or antithrombotic therapy, can include abdominal pain. Case 1 is that of a 35-year-old man at a gym who dropped a 100 kg barbell on his abdomen. It was diagnosed as a duodenal obstruction caused by a traumatic intestinal wall hematoma. In Case 2, a 16-year-old male adolescent performing deadlift training at a gym had subsequent abdominal pain. It was diagnosed as intestinal wall hematoma. Both patients improved with conservative treatment. Malignancy is sometimes suspected from imaging findings. Detailed patient history and imaging studies can avoid unnecessary surgery.
1. Technical Result Increase of efficiency of treatment of infringements of the central nervous system. 2. Essence A compound of the formula wherein A, B, X, Y, R1 – R4, n and m have the values disclosed in the description or pharmaceutically acceptable salts thereof; said compounds exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and pharmaceutical composition containing the same are useful in the treatment of central nervous system disorders. 3. Field of Application Medicine.
The invention concerns cosmetic compositions comprising: A) at least one conditioning agent selected among synthetic oils, mineral oils, vegetable oils, fluorinated and perfluorinated oils, natural or synthetic waxes, silicones, cationic polymers whereof the cationic filler density is less than 5 meq/g, cationic proteins, cationic protein hydrolysates, ceramide type compounds, cationic surfactants, fatty amines, fatty acids and their derivatives, as well as mixtures of those various compounds, and B) at least one ethylene copolymer comprising, in weight percentage based on the total weight of the polymer: a) 10-60 wt. % of one or more monomers of formula (I) as defined below; b) 40-90 wt. % of a substantially cationic monomer selected among (i) one or more cationic monomers of formula (IIa); (ii) one or more amphoteric monomers of formulae (IIc) and (IId); and (iii) a mixture of one or more cationic monomers of formula (IIa) with one or more anionic monomers selected among maleic anhydride and/or those of formula (IIb); and/or with one or more amphoteric monomers selected among those of formulae (IIc) and (IId), c) an optionally 0-50 wt. % of nonionic hydrophilic monomers, excluding methyl acrylate, methyl methacrylate and isopropyl acrylate when they are present in an amount not less than 10 wt. %. Hair treated with said compositions are more easily disentangled during rinsing, and exhibits softness after drying. The inventive compositions also allow particularly interesting hair brushing after drying.